AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comAUG 134 min read$AFYA

Afya (AFYA) Q2 Earnings and Revenues Lag Estimates

Afya (AFYA) reported Q2 adjusted EPS of $0.45, slightly below the Zacks Consensus of $0.46, versus $0.40 a year earlier. Revenue was $192.36 million, marginally under the estimate. The article cites a Zacks Rank #3 (Hold) and notes upcoming consensus for the next quarter at $0.41 EPS on $196.33 million revenue.

Original reporting
finance.yahoo.com
Published Aug 13, 2026, 11:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 1:49 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$AFYA
Bearish
medium confidence
Mentioned
$AFYA
Relevance
6/10
AlphAI data visualization · based on finance.yahoo.com
Decision brief

The 30-second read

$AFYABearishMed
01

Why it matters

Afya’s Q2 EPS and revenue both missed consensus slightly, which can pressure the stock initially; however, the article emphasizes that management commentary and subsequent estimate revisions will likely determine follow-through.

02

Market read

A modest earnings and revenue miss sets up a near-term reaction, with the earnings call and forward estimate revisions as the main trading catalyst.

03

What to watch

The article flags that estimate revisions were mixed pre-release and that forward consensus (next quarter and fiscal year) is the key driver; traders should focus on any guidance or revision updates from the call.

Relevance 6/10Novelty 6/10Timing: after-hours/next-session positioning ahead of the earnings call commentary

Background

The piece summarizes Afya’s Q2 results versus Zacks Consensus and frames what to watch next via earnings outlook and estimate revisions.

Company-level read

Ticker impact

$AFYABearishMedium confidence
Context

Afya reported Q2 EPS of $0.45, missing the $0.46 Zacks Consensus, and revenues of $192.36M slightly below consensus.

Expected impact

Choppy-to-soft near term unless the earnings call meaningfully improves forward guidance or estimate revisions.

Evidence & confidence

The article provides the miss versus consensus and notes the stock’s near-term path depends on management commentary, with the current Zacks Rank at Hold (#3).

Market effects

Sector

Adds another data point for the medical education/schools peer group, but no sector-wide reset is provided.

Regional

No regional macro or policy linkage mentioned.

Global

No global demand, regulation, or cross-border factor discussed.

Counterpoint

What could challenge this read

Despite the miss, Afya has beaten consensus EPS two times over the last four quarters, suggesting the market may be overreacting to a single quarter.

Key entities

  • company
    Afya

    Medical education company reporting Q2 EPS and revenue versus Zacks Consensus, with forward consensus discussed.

  • benchmark
    Zacks Consensus Estimate

    Street estimate reference used to quantify the EPS and revenue misses.

  • rating
    Zacks Rank #3 (Hold)

    Pre-earnings rating indicating expectations of performance in line with the market near term.

Read at source← All news

Related articles

OCT 7
$AFYAHigh

JPMorgan upgrades Afya stock rating on merger synergies

JPMorgan upgraded Afya Ltd. (AFYA) to Overweight, citing merger synergies of R$1.8 billion and a premium higher education company. The price target was lowered to $19.00 from $21.00. Afya reported Q2 2026 revenue growth of 6% and H1 growth of 7%, with net income rising 14% in Q2 and 7% in H1. The company trades at a P/E ratio of 8 and a 23% free cash flow yield.

investing.com1 min
AUG 24
$AFYAMed

Afya and Yduqs Confirm Merger Talks of Brazil’s Education Giants

Afya and Yduqs, Brazil's largest medical-education network and education group, confirmed early-stage merger talks on 24 August 2026. Yduqs shares rose 12.1% in São Paulo, while Afya's shares in New York increased 0.77%. The companies' second-quarter financials showed contrasting performances, with Afya in a stronger position. No binding agreements or details have been finalized, and both companies emphasized the preliminary nature of the discussions.

riotimesonline.com2 min
AUG 21
$AFYAMedAI 8/10

Afya (AFYA) Q2 2026 Earnings Call Transcript

Afya (AFYA) reported Q2 2026 revenue of BRL 1.985 billion, up 7% YoY. Adjusted EBITDA rose 3% to BRL 918 million, while net income increased 7% to BRL 463 million. The company faces AI competition in clinical decision tools but is integrating AI into its iClinic platform. Management reaffirmed its full-year EBITDA guidance of BRL 1.7-1.8 billion.

fool.com3 min